trending Market Intelligence /marketintelligence/en/news-insights/trending/B_yRydRWQ6gP_xBAjDn6VA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

TransEnterix's Senhance Ultrasonic system for robotic surgeries gets FDA nod

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


TransEnterix's Senhance Ultrasonic system for robotic surgeries gets FDA nod

TransEnterix Inc.'s Senhance Ultrasonic system, part of the company's robotic surgery platform for use in minimally invasive surgeries, has been approved by the U.S. Food and Drug Administration.

The Morrisville, N.C.-based medical device maker said in a Jan. 15 press release that the addition of ultrasonic technology was a significant expansion to its Senhance system, which is the first abdominal robotic surgery platform to receive FDA clearance since 2000.

The Senhance system itself is already cleared in the U.S. for laparoscopic colorectal, gynecological, inguinal hernia and gallbladder removal surgery. With the FDA nod, the Senhance Ultrasonic system is now available in the U.S., as well as all countries that accept a CE Mark designation for the product.

TransEnterix said advanced energy devices, including ultrasonic devices, are critical tools for surgeons in minimally invasive surgery as they deliver controlled energy to effectively ligate and divide tissue, while minimizing thermal injury to surrounding areas.